Skip Nav Destination
Issues
1 July 2017
-
Cover Image
Cover Image
The cover shows a section of a PyMT breast tumor treated with the pan PI3K inhibitor BKM120 (30 mg/kg daily) and PD-1-blocking antibody (100 μg twice a week). H&E staining reveals an extensive infiltration of immune cells into the treated tumors, which was associated with reduction in tumor growth and was not observed in control tumors. For details, see the article by Sai and colleagues on page 3371 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
CCR Pediatric Oncology Series: Articles from the AACR Childhood Cancer Predisposition Workshop
Retinoblastoma and Neuroblastoma Predisposition and Surveillance
Junne Kamihara; Franck Bourdeaut; William D. Foulkes; Jan J. Molenaar; Yaël P. Mossé; Akira Nakagawara; Andreu Parareda; Sarah R. Scollon; Kami Wolfe Schneider; Alison H. Skalet; Lisa J. States; Michael F. Walsh; Lisa R. Diller; Garrett M. Brodeur
Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood
Maria Isabel Achatz; Christopher C. Porter; Laurence Brugières; Harriet Druker; Thierry Frebourg; William D. Foulkes; Christian P. Kratz; Roland P. Kuiper; Jordan R. Hansford; Hector Salvador Hernandez; Katherine L. Nathanson; Wendy K. Kohlmann; Leslie Doros; Kenan Onel; Kami Wolfe Schneider; Sarah R. Scollon; Uri Tabori; Gail E. Tomlinson; D. Gareth R. Evans; Sharon E. Plon
Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma
Jennifer M. Kalish; Leslie Doros; Lee J. Helman; Raoul C. Hennekam; Roland P. Kuiper; Saskia M. Maas; Eamonn R. Maher; Kim E. Nichols; Sharon E. Plon; Christopher C. Porter; Surya Rednam; Kris Ann P. Schultz; Lisa J. States; Gail E. Tomlinson; Kristin Zelley; Todd E. Druley
Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood
Jonathan D. Wasserman; Gail E. Tomlinson; Harriet Druker; Junne Kamihara; Wendy K. Kohlmann; Christian P. Kratz; Katherine L. Nathanson; Kristian W. Pajtler; Andreu Parareda; Surya P. Rednam; Lisa J. States; Anita Villani; Michael F. Walsh; Kristin Zelley; Joshua D. Schiffman
Highlights of This Issue
CCR Translations
Reviews
Perspective
Cancer Therapy: Clinical
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty; Peter J. O'Dwyer; Jason Clark; Jack G. Shi; Kevin J. Bowman; Peggy A. Scherle; Robert C. Newton; Richard Schaub; Janet Maleski; Lance Leopold; Thomas F. Gajewski
Author Choice
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Vincent Chung; Aaron S. Mansfield; Fadi Braiteh; Donald Richards; Henry Durivage; Richard S. Ungerleider; Francis Johnson; John S. Kovach
Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Yongxian Hu; Zhao Wu; Yi Luo; Jimin Shi; Jian Yu; Chengfei Pu; Zuyu Liang; Guoqing Wei; Qu Cui; Jie Sun; Jing Jiang; Jue Xie; Yamin Tan; Wanmao Ni; Jifang Tu; Jinping Wang; Aiyun Jin; Hao Zhang; Zhen Cai; Lei Xiao; He Huang
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl; Noopur Raje; Sundar Jagannath; Paul Richardson; Parameswaran Hari; Robert Orlowski; Jeffrey G. Supko; David Tamang; Min Yang; Simon S. Jones; Catherine Wheeler; Robert J. Markelewicz; Sagar Lonial
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
Laura Bonanno; Angela De Paoli; Elisabetta Zulato; Giovanni Esposito; Fiorella Calabrese; Adolfo Favaretto; Antonio Santo; Alessandro Del Conte; Marco Chilosi; Francesco Oniga; Gabriella Sozzi; Massimo Moro; Francesco Ciccarese; Giorgia Nardo; Roberta Bertorelle; Cinzia Candiotto; Gian Luca De Salvo; Alberto Amadori; PierFranco Conte; Stefano Indraccolo
Personalized Medicine and Imaging
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Heather E. Wheeler; Eric R. Gamazon; Robert D. Frisina; Carlos Perez-Cervantes; Omar El Charif; Brandon Mapes; Sophie D. Fossa; Darren R. Feldman; Robert J. Hamilton; David J. Vaughn; Clair J. Beard; Chunkit Fung; Christian Kollmannsberger; Jeri Kim; Taisei Mushiroda; Michiaki Kubo; Shirin Ardeshir-Rouhani-Fard; Lawrence H. Einhorn; Nancy J. Cox; M. Eileen Dolan; Lois B. Travis
Author Choice
Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
Luciano Castiello; Marianna Sabatino; Jiaqiang Ren; Masaki Terabe; Hanh Khuu; Lauren V. Wood; Jay A. Berzofsky; David F. Stroncek
Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
Anosheh Afghahi; Kirsten M. Timms; Shaveta Vinayak; Kristin C. Jensen; Allison W. Kurian; Robert W. Carlson; Pei-Jen Chang; Elizabeth Schackmann; Anne-Renee Hartman; James M. Ford; Melinda L. Telli
Cancer Therapy: Preclinical
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Jiqing Sai; Philip Owens; Sergey V. Novitskiy; Oriana E. Hawkins; Anna E. Vilgelm; Jinming Yang; Tammy Sobolik; Nicole Lavender; Andrew C. Johnson; Colt McClain; Gregory D. Ayers; Mark C. Kelley; Melinda Sanders; Ingrid A. Mayer; Harold L. Moses; Mark Boothby; Ann Richmond
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Lina Han; Jeffrey L. Jorgensen; Chris Brooks; Ce Shi; Qi Zhang; Graciela M. Nogueras González; Antonio Cavazos; Rongqing Pan; Hong Mu; Sa A. Wang; Jin Zhou; Gheath AI-Atrash; Stefan O. Ciurea; Mike Rettig; John F. DiPersio; Jorge Cortes; Xuelin Huang; Hagop M. Kantarjian; Michael Andreeff; Farhad Ravandi; Marina Konopleva
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland; Amanda Watkins; Kathy A. Mulgrew; Nicholas Holoweckyj; Lisa Bamber; Natalie J. Tigue; Emily Offer; John Andrews; Li Yan; Stefanie Mullins; Michael D. Oberst; Jane Coates Ulrichsen; David A. Leinster; Kelly McGlinchey; Lesley Young; Michelle Morrow; Scott A. Hammond; Philip Mallinder; Athula Herath; Ching Ching Leow; Robert W. Wilkinson; Ross Stewart
Biology of Human Tumors
Author Choice
STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma
Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Jayanta Chatterjee; Wei Dai; Nor Haslinda Abd Aziz; Pei Yun Teo; John Wahba; David L. Phelps; Christian J. Maine; Lynsey M. Whilding; Roberto Dina; Giorgia Trevisan; Kirsty J. Flower; Andrew J.T. George; Sadaf Ghaem-Maghami
Letters to the Editor
Advertisement
